In this week’s episode, I interview David Platt, the CEO of Bioxytran. We learn about David's history of starting large publicly traded biotech and pharmaceutical companies. From there, we get into the three primary technologies that Bioxytran is working on, including a substitute for blood for trauma victims.

Guest Links

Bioxytran Website

To listen to more episodes and subscribe to the newsletter, go to ⁠⁠⁠⁠⁠⁠⁠NanoCapPod.com

Disclaimer:

The contents of this podcast are for informational purposes only and do not constitute financial, investment, legal, or other professional advice. Listeners should not construe any information discussed as a recommendation to buy, sell, or hold any securities or investments. Always consult with a qualified financial advisor or professional before making any financial decisions.